(Drug development and industrial pharmacy.[TA])
4,583 results
  • Advances in Pectin-Based Bead Formation via Ionotropic Gelation for Enhanced Drug Delivery: A Scoping Review. [Review]
    Drug Dev Ind Pharm. 2026 Jul 23; :1-25. [Online ahead of print]Schroeder Borges LH, de Luca VL, … Carneiro JDD
  • CONCLUSIONS: Pectin beads produced via ionotropic gelation have demonstrated considerable potential for controlled and colon-targeted drug delivery. However, methodological variability and limited in vivo and clinical studies still limit their translation to pharmaceutical applications. Future research should focus on process standardization, Quality by Design approaches, and hybrid polymer systems.
  • Transformable Nanosystems for Cancer Treatment. [Review]
    Drug Dev Ind Pharm. 2026 Jul 22; :1-27. [Online ahead of print]Morad H, Abdollahzadeh R, … Taghdisi SMDD
  • CONCLUSIONS: Transformable nanosystems are promising next-generation platforms for cancer therapy; however, challenges related to safety, scalability, and clinical translation remain.
  • A Review of Emerging Drug Delivery Strategies to Protect Cannabidiol from Chemical Degradation. [Review]
    Drug Dev Ind Pharm. 2026 Jul 21; :1-24. [Online ahead of print]Bazzo GC, Stulzer HKDD
  • CONCLUSIONS: The appropriate selection of CBD delivery systems is essential to ensure its chemical stability and to support the development of effective cannabinoid-based pharmaceuticals. Understanding the interplay between formulation design and storage conditions is crucial for optimizing CBD stability, extending shelf life, and ensuring the safety and efficacy of future CBD-containing therapeutic products.
  • Stimuli-responsive solid lipid nanoparticles for targeted drug delivery in biofilm-resistant infections: advances and challenges. [Review]
    Drug Dev Ind Pharm. 2026 Jul 21; :1-15. [Online ahead of print]Parameswaran D, Kanan SP, Narayanasamy DDD
  • CONCLUSIONS: Stimuli-responsive SLNs represent a promising strategy for overcoming biofilm resistance and enhancing antibiotic delivery. Although preclinical data are promising, addressing formulation challenges and improving scalability are essential for successful clinical translation. Further research on optimizing SLN design and understanding biofilm interactions will be critical for advancing SLN-based therapies for biofilm-associated infections.